Baminercept

贝奈西普

Report date: 2023/04/23 14:38:47

Base Information

Drug NameBaminercept
Drug Alias NameLymphotoxin-β receptor fusion proteinLTβR-IgBG-9924
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionTumor necrosis factor receptor superfamily member 3 inhibitors
TargetsTumor necrosis factor receptor superfamily member 3
Therapy Area/IndicationsMultiple Sclerosis, Chronic ProgressiveSjogren's SyndromeArthritis, Rheumatoid +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity of ZurichBiogen IncNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsN/A
Inactive IndicationsMultiple Sclerosis, Chronic ProgressiveSjogren's SyndromeArthritis, Rheumatoid +[4] 

Other Information

ATC CodeN/A
Related LinksKEGG